N6-methyladenosine RNA modifications: a potential therapeutic target for AML.
Rong HuPeiyun LiaoBinyan XuYingqi QiuHonghao ZhangYu-Hua LiPublished in: Annals of hematology (2023)
N6-methyladenosine (m6A) RNA modification has recently emerged as an essential regulator of normal and malignant hematopoiesis. As a reversible epigenetic modification found in messenger RNAs and non-coding RNAs, m6A affects the fate of the modified RNA molecules. It is essential in most vital bioprocesses, contributing to cancer development. Here, we review the up-to-date knowledge of the pathological functions and underlying molecular mechanism of m6A modifications in normal hematopoiesis, leukemia pathogenesis, and drug response/resistance. At last, we discuss the critical role of m6A in immune response, the therapeutic potential of targeting m6A regulators, and the possible combination therapy for AML.
Keyphrases
- acute myeloid leukemia
- immune response
- transcription factor
- healthcare
- gene expression
- dna methylation
- bone marrow
- dendritic cells
- emergency department
- toll like receptor
- squamous cell carcinoma
- squamous cell
- risk assessment
- acute lymphoblastic leukemia
- young adults
- drug induced
- childhood cancer
- lymph node metastasis